Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 3/20 | 0.33 |
| ▸ | AGXT | P21549 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30364383 | 0.79 | ALDH1A1 (0.39) | ALDH1A1MAPK1MAPTGAAPARP1 | |
| SCHEMBL25149388 | 0.79 | ALDH1A1 (0.39) | ALDH1A1MAPK1MAPTGAAPARP1 | |
| SCHEMBL19139964 | 0.78 | ACHE (0.44) | ALDH1A1MAPK1PARP1IDO1TSHR | |
| SCHEMBL20048758 | 0.77 | L3MBTL1 (0.37) | ALDH1A1MAPK1MAPTGAACYP1A2 | |
| SCHEMBL21691220 | 0.76 | CYP1A2 (0.39) | ALDH1A1MAPTCYP1A2PARP1TSHR | |
| SCHEMBL20048853 | 0.76 | CYP1A2 (0.39) | ALDH1A1MAPTCYP1A2PARP1TSHR | |
| SCHEMBL15367593 | 0.74 | CYP2A6 (0.38) | ALDH1A1MAPK1MAPTNPSR1NPC1 | |
| SCHEMBL30306598 | 0.73 | TSHR (0.41) | ALDH1A1MAPTCYP1A2TSHRRAB9A | |
| SCHEMBL21691195 | 0.73 | TSHR (0.41) | ALDH1A1MAPTCYP1A2TSHRRAB9A | |
| SCHEMBL20048857 | 0.73 | TSHR (0.41) | ALDH1A1MAPTCYP1A2TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112358424-B | Preparation method of sulfinate compound | 浙江工业大学 | 2022-06-21 | — | — | CN | disclosed |
| CN-112358424-A | Preparation method of sulfinate compound | 浙江工业大学 | 2021-02-12 | — | — | CN | disclosed |
| US-7868023-B2 | Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-11 | — | — | US | disclosed |
| US-7868023-B2 | Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-11 | — | — | US | disclosed |
| US-7868023-B2 | Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-11 | — | — | US | disclosed |
| EP-1863785-B1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-02 | — | — | EP | disclosed |
| EP-1863785-B1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-02 | — | — | EP | disclosed |
| US-20080255108-A1 | NOVEL THIOPHENE SULFOXIMINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | SUBASINGHE NALIN L | 2008-10-16 | — | — | US | disclosed |
| US-20080255108-A1 | NOVEL THIOPHENE SULFOXIMINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | SUBASINGHE NALIN L | 2008-10-16 | — | — | US | disclosed |
| US-20080255108-A1 | NOVEL THIOPHENE SULFOXIMINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | SUBASINGHE NALIN L | 2008-10-16 | — | — | US | disclosed |
| US-7385066-B2 | Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-10 | — | — | US | disclosed |
| US-7385066-B2 | Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-10 | — | — | US | disclosed |
| US-7385066-B2 | Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-10 | — | — | US | disclosed |
| EP-1863785-A1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING CMPLEMENT-MEDIATED DESEASES AND CONDITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-12 | — | — | EP | disclosed |
| US-20070066667-A1 | Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066667-A1 | Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066667-A1 | Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| WO-2006101860-A1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006101860-A1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255108-A1 | NOVEL THIOPHENE SULFOXIMINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | C5, C1R, C1QBP | ALDH1A1 1594/4885MAPK1 1619/4885MAPT 4173/4885 |
| US-20070066667-A1 | Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions | C5, C1QBP, C1R | ALDH1A1 1405/4885MAPK1 1318/4885MAPT 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.